The Relation of Standard Analgesia and Sedation Protocol in Intensive Care with Serum Procalcitonin Level

Year 2021, Volume: 8 Issue: 4, 606 - 612, 31.12.2021

Yeşim Güvenç Demirağcı İdil Tekin Orhan Kılıç Demet Aydın Tok

https://doi.org/10.34087/cbusbed.882287

Abstract

Objective: In this study, it was aimed to determine the relationship between sedo-analgesia of intensive care patients and serum procalcitonin levels.
Materials and Methods: The research was carried out retrospectively by analyzing the information from intensive care records. Before applying the sedo-analgesia protocol, the pain treatments of the patients were performed as required, according to the subjective evaluation of the patients at irregular intervals by the physicians and nurses (Group 1). With the protocol, pain and sedation needs, which were evaluated at regular intervals with reliable scales, were started to be treated with pre-determined drugs and doses (Group 2). Procalcitonin levels of the patients were measured once in the morning for 5 days.
Results: Although paracetamol was used more in group 2, there was no significant difference between the two groups. Tramadol was used statistically significantly more in group 2. Fentanyl dose did not differ significantly between the two groups. On the other hand, midazolam was used statistically significantly less in group 2. Procalcitonin levels tended to decrease gradually in both groups. When the difference between the 1st day and the 5th day was compared, no statistically significant difference was found between the two groups (p = 0.56). Serum procalsitonin median values monitored for five days were found to be similar in both groups.
Conclusion: We did not find any difference in procalcitonin levels in patients who underwent protocolized sedo-analgesia. In order to understand whether procalcitonin can be a suitable marker for pain follow-up as in infection, we think that new studies are needed in better standardized patient groups and larger case series.

Keywords

Inflammation, Intensive care, Procalcitonin, Sedoanalgesia.

Yoğun Bakımda Standart Analjezi ve Sedasyon Uygulamasının Serum Prokalsitonin Düzeyi ile İlişkisi

Abstract

Giriş ve Amaç: Bu çalışmada, yoğun bakım hastalarının tedavi sürecinde ağrı düzeylerinin kontrolünde uygulanan standart sedo-analjezinin, bir enflamasyon belirteci olan serum prokalsitonini ile ilişkisinin saptanması amaçlanmıştır.
Gereç ve Yöntemler: Araştırma, retrospektif olarak yoğun bakım kayıtlarından toplanan bilginin analizi ile gerçekleştirildi. Sedo-analjezi protokolü uygulanmadan önce hastaların ağrı tedavileri, hekim ve hemşirelerin düzensiz aralıklarla hastaları sübjektif değerlendirmeleri sonucuna göre, gereği halinde yapılmakta idi (1. Grup). Protokol ile güvenilir ölçeklerle, düzenli aralıklarla değerlendirilen ağrı ve sedasyon gereksinimleri, önceden kararlaştırılan ilaçlar ve dozlarla tedavi edilmeye başlandı (2. Grup). Hastaların prokalsitonin düzeyleri 5 gün süreyle sabah 1 kez ölçüldü.
Bulgular: Parasetamol 2. grupta daha fazla kullanılmakla birlikte her iki grup arasında anlamlı fark saptanmadı. Tramadol 2. grupta istatistiksel olarak anlamlı oranda fazla kullanıldı. Fentanil dozu iki grup arasında anlamlı farklılık göstermedi. Sedasyon amaçlı kullanılan midazolam ise 2. grupta istatistiksel olarak anlamlı oranda daha az kullanıldı. Her iki grupta da prokalsitonin değerlerinin giderek azalma gösterme eğiliminde olduğu saptandı. 1. gün ile 5. gün arasındaki fark karşılaştırıldığında iki grup arasında istatistiksel olarak anlamlı farklılık saptanmadı (p= 0,56). Beş gün boyunca izlenen serum prokalsitonin median değerlerinin her iki grupta da benzer olduğu bulundu.
Sonuç: Protokolize sedo-analjezi uygulaması yaptığımız olgularda prokalsitonin düzeylerinde bir farklılık saptamadık. Prokalsitoninin enfeksiyonda olduğu gibi ağrı takibinde de uygun bir belirteç olup olamayacağını anlamak için daha iyi standardize edilmiş hasta gruplarında ve daha geniş olgu serilerinde yeni araştırmalara gereksinim olduğu görüşündeyiz.

Keywords

Yoğun Bakım, sedoanaljezi, enflamasyon, prokalsitonin

References

• Hasegawa, R, Consideration of pain felt by patients in the ICU, Journal of Intensive Care, 2017, 5, 73-4 https://doi.org/10.1186/s40560-017-0268-2.
• Rikker, R.R, Fraser, G.L, Adverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit, Pharmacotherapy, 2005, 25(5), 8-18.
• Barr, J, Gilles, L, Fraser, P.D, Kathleen, P, et al., Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit, Critical Care Medicine, 2013, 41(1), 263-306.
• Payen, J.F, Chanques, G, Mantz, J, Hercule, C, et al., Current practices in sedation and analgesia for mechanically ventilated critically Ill patientsA prospective multicenter patient-based study, Anesthesiology: The Journal of the American Society of Anesthesiologists, 2007, 106(4), 687-695.
• 5. Tong, W, Song, C, Jin, D, Sun, J, et al., Effects of different sedation regimens on sedation and inflammatory response in critically ill children with multiple trauma, Zhonghua wei zhong bing ji jiu yi xue, 2017, 29(6), 542-546.
• Asimakopoulos, B, Demirel, C, Felberbaum, R, et al., Concentrations of inflammatory cytokines and the outcome in ICSI cycles, In Vivo, 2010, 24(4), 495-500.
• Mickiewicz, B, Tam, P, Jenne, CN, et al., Integration of metabolic and inflammatory mediator profiles as a potential prognostic approach for septic shock in the intensive care unit, Critical Care, 2015, 19, 11. https://doi.org/10.1186/s13054-014-0729-0
• Zhang, J.M, An, J, Cytokines, Inflammation and Pain, International Anesthesiology Clinics, 2007, 45(2), 27–37.
• Ramsay, M.A, Savege, T.M, Simpson, B.R, Goodwin, R, Controlled Sedation with alphaxalone-alphadolone, British Medical Journal, 1974, 22, 656-659.
• Payen, J, Bru, O, Bosson, J, Lagrasta, A, et al., Assessing Pain in Critically Ill Patients by Using a Behavioral Pain Scale, Critical Care Medicine, 2001, 29(12), s:2259.
• Chanques, G, Viel, E, Constantin, J.M, Jung, B, et al., The measurement of pain in intensive care unit: comparison of 5 self-report intensity scales, Pain, 2010, 151(3), 711-721.
• Soliman, H.M, Mélot, C, Vincent, J.L, Sedative and analgesic practice in the intensive care unit: the results of a European survey, British Journal of Anaesthesia, 2001, 87(2), 186-192.
• Alderson, S.M, McKechnie, S.R, Unregocnised, undertreated, pain in ICU: causes, effects, and how to do better, Open Journal of Nursing, 2013, 3, 108-113.
• Ringdal, M, Johansson, L, Lundberg, D, Bergbom, I, Delusional memories from the intensive care unit: experienced by patients with physical trauma, Intensive Critical Care Nursing, 2006, 22(6), 346-54.
• Ayasrah, S.M, O’Neill, T.M, Abdalrahim, M.S, Sutary, M.M, Kharabsheh, M.S, Pain assessment and management in critically ill intubated patients in Jordan: a prospective study, International Journal of Health Sciences, 2014, 8(3), 287-298.
• Yoanna, S, Ahern, S, Leblanc, M, Marquis, F, et al., Protocolized intensive care unit management of analgesia, sedation, and delirium improves analgesia and subsyndromal delirium rates, Anesthesia & Analgesia, 2010, 111(2), 451-463.
• Baddack-Werncke, U, Busch-Dienstfertig, M, González-Rodríguez, S, Maddila, SC, et al., Cytotoxic T cells modulate inflammation and endogenous opioid analgesia in chronic arthritis, Journal of neuroinflammation, 2017, 14(1), 30.
• Stein, C, Clark, JD, Uhtaek, O, Vasko, MR, et al., Peripheral mechanisms of pain and analgesia, Brain Research Reviews, 2009, 60(1), 90-113.
• Maruna, P, Nedelnikova, K, Gurlich, R, Physiology and genetics of procalcitonin, Physiol Res, 2000, 49, 57-61.
• Raddant, A.C, Russo, A.F, Reactive oxygen species induce procalcitonin expression in trigeminal ganglia glia, Headache, 2014, 54, 472-484.
• Turan, H, Horasanli, B, Ugur, M, Arslan, H, Procalcitonin levels in migraine patients, Canadian Journal of Neurological Sciences, 2011, 38, 124‐ 128.
• Hansen, J.M, Hauge, A.W, Olesen, J, Ashina, M, Calcitonin gene‐related peptide triggers migraine‐like attacks in patients with migraine with aura, Cephalalgia, 2010, 30, 1179‐1186.
• Eftekhari, S, Edvinsson, L, Possible sites of action of the new calcitonin gene‐related peptide receptor antagonists, Therapeutic Advances in Neurological Disorders, 2010, 3,369‐378.
• Park, K.Y, Russo, A.F, Control of the calcitonin gene‐related peptide enhancer by upstream stimulatory factor in trigeminal ganglion neurons, The Journal of Biological Chemistry, 2008, 283, 5441‐5451.
• Amara, S.G, Jonas, V, Rosenfeld, M.G, Ong, E.S, Evans, R.M, Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products, Nature, 1982, 298, 240‐ 244.
• Bowen, E.J, Schmidt, T.W, Firm, C.S, Russo, A.F, Durham, P.L, Tumor necrosis factor‐alpha stimulation of calcitonin gene‐related peptide expression and secretion from rat trigeminal ganglion neurons, Journal of Neurochemystery, 2006, 96, 65‐77.
• Markowitz, S, Saito, K, Moskowitz, M.A, Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain, Journal of Neurosciences, 1987, 7, 4129‐ 4136.
• Tajti, J, Kuris, A, Vecsei, L, Xu, CB, Edvinsson, L, Organ culture of the trigeminal ganglion induces enhanced expression of calcitonin gene‐related peptide via activation of extracellular signal‐regulated protein kinase ½, Cephalalgia, 2011, 31, 95‐ 105.
• Lee, Y, Takami, K, Kawai, Y, et al., Distribution of calcitonin gene‐related peptide in the rat peripheral nervous system with reference to its coexistence with substance P, Neuroscience, 1985, 15, 1227‐ 1237.
• Skofitsch, G, Jacobowitz, D.M, Calcitonin gene‐related peptide coexists with substance P in capsaicin sensitive neurons and sensory ganglia of the rat, Peptides, 1985, 6, 747‐ 754.
• Zhang, Z, Winborn, C.S, Marquez de Prado, B, Russo, A.F, Sensitization of calcitonin gene‐related peptide receptors by receptor activity‐modifying protein‐1 in the trigeminal ganglion, Journal of Neurosciences, 2007, 27, 2693‐ 2703.